Macular Degeneration St. George Utah

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Logo

In a a report made public on Sunday, 24 March, research analysts at BidaskScore’s research division boosted TRACON Pharmaceuticals (NASDAQ:TCON)‘s stock to a “Buy”.

BERGENBIO AS ORDINARY SHARES NORWAY (OTCMKTS:BRRGF) had a decrease of 20.51% in short interest. BRRGF’s SI was 24,800 shares in March as released by FINRA. Its down 20.51% from 31,200 shares previously. It closed at $4.078 lastly. It is down 0.00% since March 25, 2018 and is . It has underperformed by 4.37% the S&P500.

Analysts await TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report earnings on May, 8. They expect $-0.17 earnings per share, up 63.04% or $0.29 from last year’s $-0.46 per share. After $-0.26 actual earnings per share reported by TRACON Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -34.62% EPS growth.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $43.95 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. It currently has negative earnings. The company’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

More notable recent TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news were published by: which released: “TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update – Nasdaq” on February 28, 2019, also with their article: “Tracon +8.6% on positive test results – Seeking Alpha” published on December 26, 2018, published: “TRACON Pharmaceuticals’ Phase 2 TRAXAR trial fails to meet primary endpoints; shares down 21% premarket – Seeking Alpha” on December 21, 2018. More interesting news about TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) were released by: and their article: “TRACON Pharmaceuticals submits IND application for TJ4309 for treatment of advanced solid tumors – Seeking Alpha” published on December 26, 2018 as well as‘s news article titled: “TRACON Pharmaceuticals to Present at 2018 Wells Fargo Healthcare Conference – GlobeNewswire” with publication date: August 29, 2018.

The stock decreased 0.68% or $0.01 during the last trading session, reaching $1.47. About 443,278 shares traded. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) has declined 47.35% since March 25, 2018 and is downtrending. It has underperformed by 51.72% the S&P500. Some Historical TCON News: 23/03/2018 – TRACON PHARMACEUTICALS INC – TO USE PROCEEDS TO FUND DEVELOPMENT OF TRC105, TO CONTINUE DEVELOPMENT OF OTHER ASSETS SUCH AS TRC253; 21/03/2018 FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic; 09/04/2018 – TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors; 19/04/2018 – DJ TRACON Pharmaceuticals Inc, Inst Holders, 1Q 2018 (TCON); 09/05/2018 – TRACON Pharmaceuticals 1Q Loss/Shr 46c; 09/05/2018 – THROMBOGENICS NV THR.BR – FIRST PATIENT ENROLLED IN PHASE 2 STUDY EVALUATING ANTI-PLGF (THR-317) IN COMBINATION WITH ANTI-VEGF (RANIBIZUMAB, LUCENTIS®) IN PATIENTS WITH DME; 10/04/2018 – TRACON PHARMACEUTICALS SAYS REGARDING ELECTION OF TED WANG TO BOARD, BOARD APPROVED AN INCREASE IN SIZE FROM SIX TO SEVEN MEMBERS – SEC FILING; 22/03/2018 – Roche’s Lucentis 0.3 Mg Prefilled Syringe Receives FDA Approval; 23/03/2018 – TRACON Pharmaceuticals Enters into Agreement for $38.7M Private Placement; 21/03/2018 – GENENTECH – PREFILLED SYRINGE OPTIONS ARE NOW FDA-APPROVED FOR ALL LUCENTIS INDICATIONS

Source link

The global macular degeneration treatment market was valued at US$ 6.1 Bn in 2017. It is anticipated to reach US$ 11.1 Bn by 2026, expanding at a CAGR of 6.4% from 2018 to 2026. Increase in R&D investments by key players has resulted in innovative products. Increase in prevalence and incidence of retinal disorders, rise in the geriatric population, high annual cost of therapy (ACOT) for pipeline drugs, improved health care as well as health care infrastructure, introduction of novel therapies, and surge in the number of awareness programs are likely to drive the global macular degeneration treatment market during the forecast period. Continued pressure from players mandating the use of Avastin for wAMD and invasive administration methods are anticipated to restrain the global market in the near future. However, developed countries, such as Japan, Germany, the U.S, Canada, France, and Australia offer immense opportunities to the macular degeneration treatment market. This is attributed to the large number of patients, rise in proportion of urban population, and high reimbursement.

The global macular degeneration treatment market has been segmented based on disease indication, drug class, distribution channel, and region. Based on disease indication, the wAMD segment is projected to lead the market, in terms of revenue, and dominate the market during the forecast period, followed by the dAMD segment. Introduction of new anti-VEGF drugs, such as brolucizumab, and less frequent administration regimen in the existing anti-VEGF (Eylea) for treatment of wAMD are estimated to propel the segment.

In terms of end-user, the global macular degeneration treatment market has been categorized into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment accounted for a major share of the global macular degeneration treatment market in 2017. The segment is likely to maintain its leading position during the forecast period. A large population prefers to visit a hospital first rather than an ophthalmic clinic for treatment, as the cost of therapy at a hospital is lower. An ambulatory surgical center is a relatively less preferred option for the treatment of AMD.

Request for Report Sample:

In terms of drugs, the global macular degeneration treatment market has been classified into anti-VEGF and others. The anti-VEGF segment accounted for a major share of the global macular degeneration treatment market in 2017. In 2007, Lucentis became the first anti-VEGF launched for wet AMD as well as other important retinal diseases. It was quickly recognized as the new gold standard for treatment. In 2013, Eylea was also approved for AMD and launched at a marginally lower price; other indications were later added. However, the launch of Novartis’ longer-acting anti-VEGF, brolucizumab is projected to boost the wAMD segment during the forecast period by replacing some use of inexpensive Avastin.

In terms of region, the global macular degeneration treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global macular degeneration treatment market, in terms of revenue, in 2017. It is projected to maintain its dominance during the forecast period. High rate of adoption of prescription AMD disease drugs in the U.S. and increase in the number of approvals for new drugs from the U.S. FDA are major factors responsible for the high share held by North America in 2017. Asia Pacific is anticipated to gain market share during the forecast period owing to a large patient pool, increasing per capita health care expenditure, and increasing investment by key players in this market.

Major players operating in the global macular degeneration treatment market are Allergan, Inc., Pfizer, Inc., Novartis AG., REGENERON PHARMACEUTICALS, INC., Ophthotech, Santen Pharmaceuticals, Valeant Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sanofi, Ohr Pharmaceutical, Apellis, and Bayer AG. The market is characterized by a large number of acquisitions, which has led to market consolidation and increasing dominance of the top players.

Obtain Report Brochure:

Post Views:

Source link

Eye Associates of New Mexico Patient Is First in State to Receive a Telescope Implant for Macular Degeneration after Previous Cataract Surgery.

Source link

SAN CARLOS, Calif., March 25, 2019 /PRNewswire/ — Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, shared results yesterday from its open label study, ALK4290-201. The data were delivered during a podium presentation as the Abstract Winner of the First-time Presentations of Clinical Trials and Late Breakers session at the 2019 Retina World Congress. The study evaluated the therapeutic effect and safety of the small molecule, AKST4290, formerly known as ALK4290, for the treatment of wet or neovascular age-related macular degeneration (nAMD) in treatment-naïve patients.

“Age-related macular degeneration is the leading cause of age-related blindness,” said Karoly Nikolich, Ph.D, co-founder and chief executive officer of Alkahest. “Today, the standard of care for this disease involves burdensome intravitreal injections, which can result in under-treatment of patients over time. Alkahest’s data show the potential for an orally-administered agent to safely increase visual acuity in nAMD, which would be a true medical advance for patients.”

Data demonstrated that AKST4290, a highly selective and potent small molecule antagonist of CCR3, was safe, well-tolerated, and provided a mean increase in Best Corrected Visual Acuity (BCVA) in naïve nAMD trial subjects. Measured in terms of letters gained according to the ETDRS system, 83% of subjects’ eyes had maintenance or improvement of BCVA, with a mean of +7 letters gained. Twenty-one percent of subjects gained > 15 letters. Investigators also observed trends in morphological changes in retinal pigment epithelium (RPE) detachment height in correlation with increases in BCVA, which will be further investigated in future trials. No serious adverse events or discontinuations due to adverse events were seen in the trial, and the drug was well tolerated. 

Dr. Michael Stewart, Chair, Department of Ophthalmology at the Mayo Clinic, Jacksonville commented: “These early data for AKST4290 are extremely promising, showing an impressive increase in visual acuity even over a short 6-week period of treatment. The potential for gaining meaningful visual improvement with an oral agent in neovascular AMD represents a major step forward for patients. Based on the data, it is clear these encouraging results warrant further study.”

Alkahest also conducted the AKST4290-202 study, a parallel Phase 2a clinical trial designed to evaluate the therapeutic effects and safety of the same treatment regimen in patients with refractory nAMD no longer responding to anti-VEGF therapy. Data from this trial will be presented later in 2019.

About ALK4290-201
The ALK4290-201 study was a Phase 2a trial that evaluated the therapeutic effects and safety of a six-week, oral treatment regimen of AKST4290 400mg twice per day (800mg total) in newly diagnosed nAMD patients naïve to anti-VEGF treatment. The study included 29 evaluable subjects. The primary endpoint was mean change in best corrected visual acuity (BCVA) measured according to the Early Treatment Diabetic Retinopathy Study (ETDRS) system. Safety was the secondary endpoint, measured by the incidence and severity of adverse events. Exploratory endpoints included therapeutic effect on disease morphology and an exploration of biomarkers, which is ongoing.

About AKST4290
AKST4290 is an orally administered CCR3 inhibitor that blocks the action of eotaxin, an immunomodulatory protein that increases as humans age and with specific age-related diseases. By targeting eotaxin and its downstream effects, AKST4290 may reduce the hallmark inflammation and neovascularization of wet AMD while also acting more broadly to reduce inflammation associated with many other age-related diseases.

About Alkahest 
Alkahest is a clinical stage biopharmaceutical company dedicated to treating neurodegenerative and age-related diseases with transformative therapies targeting the aging plasma proteome. The Alkahest pipeline includes multiple therapeutic candidates ranging from selected plasma fractions to protein-targeted interventions which aim to slow the detrimental biological processes of aging. Alkahest is developing novel plasma-based therapies in collaboration with Grifols, a global healthcare company and leading producer of plasma therapies. For further information see or follow us on Twitter @AlkahestInc

Contact Information 
Elizabeth Jeffords 
Chief Commercial & Strategy Officer 
Alkahest, Inc. 

Media Contact 
Michael Tattory 
LifeSci Public Relations 

SOURCE Alkahest, Inc.

Related Links

Source link

There is no greater thrill for runners than breaking the tape, and for marathon men and women just seeing the finish line has to be a sensation to savor.

The sport is exhilarating for Juli Brandvold, who in a few weeks will run on the most famous marathon course in America. Boston will be the first marathon for the 42-year-old Great Falls woman.

And the finish line? Well, that will be a sight for sore eyes.

Even though she can’t really see it.  

More: Follow Scott Mansch’s columns, support local journalism with a special subscription offer

“I can feel it, though,” Julie says softly. “They have little bumps to start and stop the times.”

She laughs.

“I’ll feel it,” she says. “And I’ll hear it, if there’s people screaming. I think I’ll know.”

AS A YOUTH, Juli was afflicted with a genetic disease called Stargardt’s Macular Distrophy. She was diagnosed at age 10.

“It’s the juvenile form of macular degeneration,” she says.

The severity?

“I definitely can’t ever drive,” Juli says. “That would be bad. I can sort of watch TV, but it’s like if you have glasses and you put Vaseline spots on them.”

She graduated from Simms High in 1995 and has lived in central Montana most of her life. Juli is a licensed massage therapist. She’s also a runner.

“Well, I’m trying to be,” she laughs. “I’m pretty slow.”

But what’s that they say about slow and steady? Juli knows all about a steady, sturdy upbringing.

“I grew up on a farm, and I had to do chores just like my siblings,” Juli says.

You see, even though her eyes didn’t function properly, Juli wasn’t shielded from the workload.

“I wasn’t treated like, ‘Oh, you can’t do that’ or ‘You gotta do this,’ or ‘Oh, you gotta be careful,’ “ she says. “I was just treated like a normal kid. That really helped. I think parents can be a blind kid’s worst problem.”

HER MOTHER, MARY, is and always has been an important person in Juli’s life. Her father, though, died in a car accident about 30 years ago, after which the family relocated from North Dakota to central Montana.

Juli is obviously no stranger to hardship. How has she managed to cope?

“I know plenty of depressed blind people, but I also know plenty of depressed sighted people as well,” she says.

She thinks for a moment.

“What’s that old saying?” she says. “Getting busy living or get busy dying? Well, you can sit around and be depressed, or figure out what you can do to make your life livable and happy.”

Running has certainly helped Juli be happy.

“Oh yeah,” she says with a laugh. “I’m a much better person to be around. It just helps. It really helps. You’ve got to have some sort of outlet, and it’s helped me out big-time.”

IT ALL STARTED four years ago.

“I used to never think of running,” Juli laughs. “Like why would I want to do that? I grew up with horses. If I wanted to get somewhere I rode horses.”

A desire to get into better physical condition led a friend, Lindsey Nussbaum, to suggest a running regimen.

“Lindsey, he’s been my training partner,” Juli says.

Vision-impaired athletes who run need guides, and Lindsey has filled that role for Juli. Not really an experienced long-distance runner, several years ago he told her with a chuckle the only way he’d ever get to the famous Boston Marathon was as a guide.

“So I said ‘OK, let’s do that then,’” Juli laughs. “I don’t think he thought I’d taken him seriously.”

Oh but she had.

JULI AND LINDSEY are good friends and have been for several years. They used to go on occasional hikes together. But Juli says she was not a serious athlete.

“Basically went from a coach potato to running,” she says. “It took a while.”

A stress fracture made the progress especially slow. Juli’s first actual race was the “Burn The Bird,” an annual Thanksgiving 5K (3.1 miles) in Great Falls that most folks run mainly for recreation.

A 10K race followed, then two years ago Juli and Lindsey ran a half-marathon (13.1 miles).

Last year she and Lindsey finished a full marathon in southern California that qualified her for a trip to the famous Boston Marathon.

HOW WAS SHE able to make such progress as a long-distance runner?

“I’ve had some pretty good support,” Juli says. “I like certain spots here in Great Falls on the River’s Edge Trail. I know that trail pretty well, so I can do it by myself. I can see the contrast of the asphalt to the snow or grass or whatever.”

She laughs.

“Once in a while I’ll hit a curve and go straight, and I’ll hit some gravel,” she says. “Then I know ‘Whoops, I have to turn.’ I wear a special vest, too, so other people know ‘If I run into you, this is why.’ “

Many runners, of course, enjoy the scenery while training. That’s not really possible for Juli.

“Not so much,” she says. “But I want to be healthy.”

And that’s both physically and mentally.

“It’s really helped me both ways,” she says. “You know, winters here can be tough. And life, being vision-impaired, can be tough.”

She pauses a second.

“It’s important to find ways to be both mentally and physically fit,” Juli says softly. “For me, it was a necessity. I needed to do something. So running, and having a goal like that — even though it’s a big one — helps keep me focused.”

JOY LOAGUE HAS taught water aerobics in Great Falls for 35 years, during which time she’s met hundreds and hundreds of people.

Juli stands out. And not just because she’s been one of Joy’s regular customers.

It’s because she’s been a loyal friend.

“That’s right,” says Joy, who will be 79 soon and needs shoulder surgery in addition to the two knees and hip she’s had replaced. “Juli’s very dependable and very nice. She’s just happy-go-lucky.

“She’s there for me and I’m there for her. She looks out for me.”

Even though she can’t really see.

To lose one’s vision is a frightening proposition. But Juli, who owns her own home and works — and works out — regularly, tackles life without fear.

“Juli is scared of ice,” says Joy. “That’s really the only thing. Otherwise she’s a rock and she just goes and goes.”

JULI WILL BE running in Boston to benefit an organization called the Massachusetts Association for the Blind and Visually Impaired.

She has a gofundme site at that folks can visit.

Juli and Lindsey plan to get to Boston early in order to sight-see. Well, Juli will not see nearly as much as the normal tourist.

“For me, it’s all about contrast,” she says. “So if there’s contrasting colors I can make it out pretty good. I can get a pretty decent sense. And Lindsey is very good at describing things.”


Juli will be among about 75 “mobility-impaired” runners who have qualified. She’s the only Montanan in that category. She’s also among three registered runners from Great Falls who are planning to run, joining Chad Olson and Kim Ray.

The goal, Juli says, is to complete the race in about four hours, 45 minutes. That would be a bit quicker than she ran the 26.2 miles in southern California.

“I’m definitely not elite by any means,” she laughs.

Oh, but she is. She truly is.

Her personality and perseverance prove as much.

Mansch On Montana, dedicated to personalities and places that make living in the Treasure State so special, appears frequently. Scott Mansch can be reached at 791-1481 or

Read or Share this story:

Source link

  • AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides for cancer, adds Steven Altschuler, MD to Board of Directors.
  • Dr. Altschuler, the founder and Chairman of the Board of Spark Therapeutics Inc. (ONCE), brings to AsclepiX a deep knowledge and experience in developing novel therapies for the treatment of retinal disease.

BALTIMORE, MD / ACCESSWIRE / March 25, 2018 / AsclepiX Therapeutics, Inc, a biopharmaceutical company focused on developing vital new therapies based on a novel collagen IV-derived peptide called AXT107, announces that Steven Altschuler, MD has joined its Board of Directors. Dr. Altschuler, who formerly held Chief Executive positions at the Children’s Hospital of Pennsylvania (CHOP) and University of Miami Health System (UMHS), brings significant strategic and operational experience to AsclepiX. As a Board Member, Dr. Altschuler will help AsclepiX succeed and scale as it commercializes its flagship product, AXT107, and their products for cancer.

Dr. Altschuler has 18 years of experience growing healthcare organizations in business and leadership capacities. Trained as a pediatric gastroenterologist, he was appointed in 2000 as President & CEO at CHOP, where he also chaired the Department of Pediatrics. For 15 years, he played a pivotal role transforming CHOP from a traditional academic medical center to a highly integrated, value-based translational health system characterized by world-class clinical care. Under his purview, the organization enjoyed financial success and earned industry accolades, ranking as the #1 children’s hospital by US News and World Report 10 times during his 15-year tenure – and the #2 hospital during the remaining 5 times. He then went on to serve as CEO and Executive Vice President of UMHS, where he restructured the clinical delivery system into a CMS, Perspective Payment System (PPS)-exempt unified academic medical center under a single state license.

In 2013, Dr. Altschuler founded Spark Therapeutics, Inc. (NASDAQ: ONCE) based on technology and know-how developed over two decades at Children’s Hospital of Philadelphia (CHOP). He serves as Chairman of the Board at Spark Therapeutics, Inc., a fully integrated, commercial company committed to discovering, developing and delivering gene therapies across multiple therapeutic categories. In 2017, Spark gained FDA approval for LUXTURNA® (voretigene neparvovec-rzyl), a one-time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and which is currently marketed in the US. The European Commission granted marketing authorization for LUXTURNA in 2018. Most recently, Spark Therapeutics, Inc. is in the process of being acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY) for $4.8 billion.

“The AsclepiX team is proud to make Dr. Altschuler a member of our Board,” said Wendy Perrow, CEO of AsclepiX Therapeutics. “His track record of success in the development and approval of a novel gene therapy for blindness due to inherited retinal disease should prove invaluable to our team as we move into clinical development of AXT107 for acquired retinal diseases, including Diabetic Macular Edema and wet Aged-Related Macular Degeneration. Furthermore, his expertise in developing technology that originated in the academic laboratories of CHOP will translate well to AsclepiX, which is developing novel therapeutics through a peptide platform developed in the laboratories at John’s Hopkins University. Dr. Altschuler’s perspective and guidance will be invaluable as we continue to innovate and bring exciting new therapies to the ophthalmic and oncology markets.”

In addition to his work with Spark and AsclepiX, Dr. Altschuler currently holds leadership and advisory positions on several corporate boards, including Adtalem Global Education (Member, Board of Directors) and WW (formerly Weight Watchers International; Member, Board of Directors). He previously held board positions at Mead Johnson Nutrition Company and the Leonard Davis Institute of Healthcare Economics at the Wharton School, University of Pennsylvania.

About AsclepiX Therapeutics, Inc.
AsclepiX Therapeutics Inc. is transforming the treatment of ocular diseases and cancer with a singular focus on a novel peptide platform with the power to inhibit and potentially even reverse disease progression. The mechanism of action of AXT107 targets multiple pathways, including inhibiting vascular endothelial growth factor receptor 2 (VEGFR2) and activating Tie2, two pathways that promote formation of blood vessels and leakage of fluid in the diseased retina that may be dosed 1 – 2 times per year. AsclepiX is initially focused on ocular diseases currently treated with anti-VEGF monotherapies. Learn more at

Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development of AsclepiX Therapeutics, Inc. products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. AsclepiX Therapeutics, Inc. undertakes no obligation to update any forward-looking statements for any reason.

Media contact:
Amy Phillips

SOURCE: AsclepiX Therapeutics, Inc.

View source version on

Source link

Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market examine and study the market position and forecast related with production, consumption, cost structure, and historical data. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market report provides company, products, end-user, top countries, growth trends, future prospects, segments and sub-segments.Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs  Market Include Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure, and operations. The Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs  Market report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

Top Manufacturers in global market are

Novartis, Bayer Healthcare, Roche, Neurotech Pharmaceuticals, Regeneron Pharmaceuticals, Allergan

Ask & Get Sample Copy of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Report @

The study report is bifurcated into the following regions on the basis of topography: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

** Influence of the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market report **

 Comprehensive assessment of all opportunities and risk in the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market.

 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market recent innovations and major events.

 Detailed study of business strategies for growth of the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market-leading players.

 Conclusive study about the growth plot of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market for forthcoming years.

 In-depth understanding of Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market-particular drivers, constraints and major micro markets.

 Favorable impression inside vital technological and market latest trends striking the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert @

Product Type Segment Analysis:

* Macular Degeneration Drugs
* Diabetic Retinopathy Drugs

Applications Segment Analysis:

* 50-60 Years Old
* 60-70 Years Old
* Other

Key Reasons to Purchase:

 To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

 Assess the production processes, major issues, and solutions to mitigate the development risk.

 To understand the most affecting driving and restraining forces in the Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market and its impact in the global market.

 Learn about the market strategies that are being adopted by leading respective organizations.

 To understand the outlook and prospects for the market.

Our Blog :

Dynamic Analyst

Get More Research Reports Here:

Source link

DURHAM, N.C.–()–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
the appointment of David Ellis, Ph.D., as Director, Chemistry, reporting
to Mitchell deLong, Ph.D., Aerie’s Vice President of Chemistry. Dr.
Ellis will be responsible for advancing the Company’s creation and
optimization of new chemical entities to support the growth and
advancement of Aerie’s pipeline. Dr. Ellis most recently held a related
position at Novartis. Aerie also announced the appointments of Angela
Justice as Western Regional Director, Medical Science Liaison and Brian
Sakurada, PharmD, Director, Scientific Market Access, both reporting to
Welyn Bui, PharmD, Aerie’s Vice President of Medical Affairs. Ms.
Justice will be responsible for leading a regional team of Medical
Science Liaisons engaged in developing relationships with medical
experts in the field of glaucoma to ensure a fair and balanced exchange
of scientific, clinical and medical information. Ms. Justice most
recently held a related position at Sun Pharmaceuticals. Dr. Sakurada
will be responsible for further developing the medical affairs strategy
including delivery of evidence-based scientific information and
outcome-based information to national and regional payer accounts. Dr.
Sakurada most recently held a related position at Intarcia Therapeutics.
Aerie also announced the appointment of Karisma Sharma as Vice
President, Human Resources, reporting to Kathy McGinley, Aerie’s Vice
President of Human Resources and Corporate Services. Ms. Sharma will be
responsible for leading the strategic human resources effort to recruit,
develop and retain employees in the United States. Ms. Sharma previously
held related positions in both healthcare and technology companies.

In connection with their acceptance of their positions, Dr. Ellis, Ms.
Justice, Dr. Sakurada and Ms. Sharma will receive combined awards
totaling 87,260 stock options and 2,000 shares of restricted stock. The
stock options will vest over 4 years, with 25% vesting on the first
anniversary of the hire date and the remainder vesting ratably on each
of the subsequent 36 monthly anniversaries of the hire date; the
restricted stock will vest over a period of 4 years in four equal annual
installments on each anniversary of the hire date. This award was made
outside of Aerie’s stockholder-approved equity incentive plan and was
approved by the Company’s independent directors as inducements material
to Dr. Ellis, Ms. Justice, Dr. Sakurada and Ms. Sharma entering into
employment with the Company in reliance on NASDAQ Listing Rule
5635(c)(4), which requires this public announcement.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retinal diseases and
other diseases of the eye. Aerie’s first product, Rhopressa®(netarsudil
ophthalmic solution) 0.02%, a once-daily eyedrop approved by the U.S.
Food and Drug Administration (FDA) for the reduction of elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More information
about Rhopressa®, including the product label, is available
Aerie’s second product for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, Rocklatan (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose
combination of Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost, has been
approved by the FDA and is expected to be launched in the United States
in the second quarter of 2019. In clinical trials of Rocklatan, the
most common adverse reactions were conjunctival hyperemia, corneal
verticillata, instillation site pain, and conjunctival hemorrhage. More
information about Rocklatan,  including the
product label, is available at
Aerie continues to focus on global expansion and the development of
additional product candidates and technologies in ophthalmology,
including for wet age-related macular degeneration and diabetic macular
edema. More information is available at

Forward-Looking Statements

This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,”
“will,” “should,” “exploring,” “pursuing” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: our
expectations regarding the commercialization and manufacturing of
Rhopressa® and Rocklatan™ or any future product candidates,
including the timing, cost or other aspects of the commercial launch of
Rhopressa® and Rocklatan™ or any future product candidates;
our commercialization, marketing, manufacturing and supply management
capabilities and strategies; the success, timing and cost of our ongoing
and anticipated preclinical studies and clinical trials for Rhopressa®
and Rocklatan™, with respect to regulatory approval outside of the
United States or additional indications, and any future product
candidates, including statements regarding the timing of initiation and
completion of the studies and trials; the timing of and our ability to
request, obtain and maintain FDA or other regulatory authority approval
of, or other action with respect to, as applicable, Rhopressa®,
Rocklatan™ or any future product candidates, including the expected
timing of, and timing of regulatory and/or other review of, filings for,
as applicable, Rhopressa®, Rocklatan™ or any future product
candidates; the potential advantages of Rhopressa® and
Rocklatan™ or any future product candidates; our plans to pursue
development of additional product candidates and technologies within and
beyond ophthalmology; our plans to explore possible uses of our existing
proprietary compounds beyond glaucoma, including development of our
retina program; our ability to protect our proprietary technology and
enforce our intellectual property rights; and our expectations regarding
strategic operations, including our ability to in-license or acquire
additional ophthalmic products, product candidates or technologies. By
their nature, forward-looking statements involve risks and uncertainties
because they relate to events, competitive dynamics, industry change and
other factors beyond our control, and depend on regulatory approvals and
economic and other environmental circumstances that may or may not occur
in the future or may occur on longer or shorter timelines than
anticipated. We discuss many of these risks in greater detail under the
heading “Risk Factors” in the quarterly and annual reports that we file
with the Securities and Exchange Commission (SEC). In particular, FDA
approval of Rhopressa® and Rocklatan™ do not constitute FDA
approval of AR-1105, AR-13503 or any future product candidates, and
there can be no assurance that we will receive FDA approval for AR-1105,
AR-13503 or any future product candidates. FDA approval of Rhopressa®
and Rocklatan™ also do not constitute regulatory approval of Rhopressa®
and Rocklatan™ in jurisdictions outside the United States and there can
be no assurance that we will receive regulatory approval for Rhopressa®
and Rocklatan™ in jurisdictions outside the United States.
Forward-looking statements are not guarantees of future performance and
our actual results of operations, financial condition and liquidity, and
the development of the industry in which we operate may differ
materially from the forward-looking statements contained in this press
release. Any forward-looking statements that we make in this press
release speak only as of the date of this press release. We assume no
obligation to update our forward-looking statements whether as a result
of new information, future events or otherwise, after the date of this
press release.

Source link

Age Related Macular Degeneration Treatment

The Global Age Related Macular Degeneration Treatment Market report 2019 offers a deep analysis of the Age Related Macular Degeneration Treatment trade. It demonstrates a quick outline of trade knowledge and key terminology of the market. The report highlights well-known performers from the worldwide and Age Related Macular Degeneration Treatment Market along with their contribution to the market to see their progress at intervals the calculable time. the worldwide Age Related Macular Degeneration Treatment analysis report covers recent enhancements whereas predicting the expansion of the most players together with their market shares.

Get Sample Copy of this Report(Corporte Email Address Only);@

The Global Age Related Macular Degeneration Treatment Market Forecast 2023 Report Description: Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for €œstraight-ahead€ activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.

Company Coverage of Age Related Macular Degeneration Treatment market (Sales Revenue, Price, Gross Margin, Main Products etc): 

Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma

Age Related Macular Degeneration Treatment Market Types: , Lucentis, Eylea, Avastin, Other

Age Related Macular Degeneration Treatment Market Applications: Market Segment by Type, covers:, Lucentis, Eylea, Avastin, OtherMarket Segment by Applications, can be divided into, Hospital, Clinic, Other

Scope of the Report:

,The worldwide market for Age Related Macular Degeneration Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new study.,This report focuses on the Age Related Macular Degeneration Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.,,


Age Related Macular Degeneration Treatment market along with Report Research Design:

Age Related Macular Degeneration Treatment Market Historic Data (2013-2018):

Industry Trends: Global Revenue, Status, and Outlook.

Competitive Landscape: By Manufacturers, Development Trends.

Product Revenue for Top Players: Market Share, Growth Rate, Current Market Situation Analysis.

Market Segment: By Types, By Applications, By Regions/ Geography.

Sales Revenue: Market Share, Growth Rate, Current Market Analysis.

Age Related Macular Degeneration Treatment Market Influencing Factors:

Market Environment: Government Policies, Technological Changes, Market Risks.

Market Drivers: Growing Demand, Reduction in Cost, Market Opportunities and Challenges.

Age Related Macular Degeneration Treatment Market Forecast (2018-2023):

Market Size Forecast: Global Overall Size, By Type/Product Category, By Applications/End Users, By Regions/Geography.

Key Data (Revenue): Market Size, Market Share, Growth Rate, Growth, Product Sales Price

Price of Age Related Macular Degeneration Treatment Market Report (SUL): $ 3480

Purchase Direct Report @

Global Age Related Macular Degeneration Treatment Market Region Coverage (Regional Output, Demand & Forecast by Countries etc.):

North America(the United States, Canada, and Mexico)

Europe(Germany, UK, France, Italy, Russia, Spain, and Benelux)

Asia Pacific(China, Japan, India, Southeast Asia, and Australia)

Latin America(Brazil, Argentina, and Colombia)

The Middle East and Africa.

Reasons for Buying this Age Related Macular Degeneration Treatment Market Report: –

The beer industry report gives precise analysis for changing competitive dynamics.

It gives progressive lookout of different factors driving or operating or regulating market growth.

It provides future growth on the basis of assessment of the Five-year forecast report.

This report gives a technological growth map over time to recognize understand the industry growth rate.

The report helps in understanding the significant product components and their future.

In the end, the Age Related Macular Degeneration Treatment Market report includes investment come analysis and development trend analysis. The key rising opportunities of the fastest growing international Age Related Macular Degeneration Treatment industry segments are coated throughout this report. This report additionally presents product specification, producing method, and products cost structure. Production is separated by regions, technology, and applications.

In conclusion, it is a deep research report on Global Age Related Macular Degeneration Treatment industry. If you have any special requirements, please let us know and we will offer you the report as you want @

Table of Content:

Age Related Macular Degeneration Treatment Introduction and Market Overview (Objectives of the Study, Definition of Age Related Macular Degeneration Treatment )

Market Scope and Market Size Estimation

Market Concentration Ratio and Market Maturity Analysis

Global Value and Growth Rate from 2013-2023(Market Segmentation, Types of Age Related Macular Degeneration Treatment, Applications of Age Related Macular Degeneration Treatment, Research Regions)

Market Dynamics (Drivers, Limitations, Opportunities)

Industry News and Policies by Regions (Industry News, Industry Policies)

Industry Chain Analysis(Upstream Raw Material Suppliers of Age Related Macular Degeneration Treatment Analysis, Major Players, Major Players Manufacturing Base and Market Share in 2018, Major Players Product Types in 2018

Age Related Macular Degeneration Treatment Manufacturing Cost Structure Analysis (Production Process Analysis, Manufacturing Cost Structure of Age Related Macular Degeneration Treatment, Raw Material Cost, Labor Cost )

Market Channel Analysis of Age Related Macular Degeneration Treatment

Major Downstream Buyers of Age Related Macular Degeneration Treatment Analysis

Global Market, by Type (Global Age Related Macular Degeneration Treatment Value, Production, Market Share, Price Analysis and Growth Rate by Type)

Age Related Macular Degeneration Treatment Market, by Application (Downstream Market Overview, Global Age Related Macular Degeneration Treatment Consumption, Growth Rate and Market Share by Application)

Global Production, Value ($) by Region (2013-2018) (Production, Value, Price and Gross Margin, Market Share by Region)

Global Production, Consumption, Export, Import by Regions (2013-2018) (Global, North America, Europe, China, Japan, South America, India & the Middle East and Africa)

Global Market Status and SWOT Analysis by Regions

Competitive Landscape (Competitive Profile: Company Profiles, Product Introduction, Company Production, Value, Price, Gross Margin 2013-2018E, Market Share of Age Related Macular Degeneration Treatment Segmented by Region in 2018)

New Project Feasibility Analysis (Industry Barriers and New Entrants SWOT Analysis, Analysis and Suggestions on New Project Investment)

Research Finding and Conclusion



About Us:
Marketreportsworld is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

Name: Ajay More
Email: [email protected] 
Organization: marketreportsworld
Phone: US +14242530807/UK +442032398187

Source link

Anti-vascular endothelial growth factor (VEGF) agents such as pegaptanib, ranibizumab, and bevacizumab maintain visual acuity in patients with neovascular age-related macular degeneration (AMD), according to a new review.

Investigators found that patients with anti-VEGF agents were better than no aint-VEGF agents or other types of treatment for patients with wet AMD. In studies comparing anti-VEGF agents, the researchers found that ranibizumab and bevacizumab were similar in terms of vision-related outcomes and number of adverse events; the major difference was cost, as bevacizumab was cheaper. 

Investigators, from Johns Hopkins University School of Medicine, sought to further investigate oculate and systemic effects of intravitreous injection of three anti-VEGF agents as well as their impact on quality of life. The investigators compared pegaptanib, ranibizumab, and bevacizumab compared to no anti-VEGF treatment in patients with AMD.

Investigators reviewed eligible studies from various literature databases and did not impose date or language restrictions on their search. They identified 16 randomized controlled trials through January 2018 with a total of 6347 participants diagnosed with AMD, though the participants per trial ranged from 23 to 1208. Of those 16 trials, 6 compared pegaptanib, ranibizumab, or bevacizumab to control treatment and 10 trials compared bevacizumab against ranibizumab.

The investigators determined that more patients who were treated with any of the anti-VEGF treatments compared to control subjects had gained 15 or more letters of visual acuity, had lost fewer than 15 letters of visual acuity and showed mean improvement of visual acuity after one year. In one pegaptanib trial, the investigators found a mean difference of 6.7 letters from 4.4 to 9.0. Among three ranibizumab trials, they found a mean difference of 17.8 letters from 16.0 to 19.7. Despite the lower cost of bevacizumab compared to ranibizumab, this remained true.Compared to control treatments, ranibizumab and bevacizumab treatments showed larger visual acuity outcomes than pegaptanib. No trial directly compared pegaptanib to another anti-VEGF agent.

Investigators found that AMD patients treated with ant-VEGF agents showed improvement in morphologic outcomes, including size of choroidal neovascularization and central retinal thickness, compared to those not treated with the agents. Central retinal thickness reduction was less among patients treated with bevacizumab compared to those treated with ranibizumab after one year, they added. Investigators added that the difference may not be clinically meaningful.

The most frequently reported serious ocular adverse events were ocular inflammation and increased intraocular pressure (IOP) after injection. Investigators reported endophthalmitis in less than 1% of anti-VEGF-treated patients and in no control patients. Serious systemic adverse events were comparable across treated and untreated patient cohorts. The varying study sizes might not be able to accurately depict meaningful differences between the group.

The investigators also found that researchers rarely measured and reported visual function, quality of life, or economic outcome data.

“Anti‐VEGF agents were better than no anti‐VEGF agents or other types of treatment for patients with wet AMD,” the study authors concluded. “When studies compared anti‐VEGF agents, researchers found that ranibizumab and bevacizumab were similar in terms of vision‐related outcomes and numbers of adverse events among participants followed for at least one year. The major difference was cost, as bevacizumab was cheaper.”

The paper, titled “Anti-vascular endothelial growth factor for neovascular age-related macular degeneration,” was published in the Cochrane Database of Systematic Reviews.  


Source link